Papers, abstracts, presentations, posters and webcasts emanating from the audit
Webcast of ABCD liraglutide and exenatide audits research fellow, Dr Ken Thong, presenting his paper at the EASD in Stockholm, September 22, 2010:
Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit
Webcast of former ABCD liraglutide and exenatide audits research fellow, Dr Ken Thong, presenting his paper at the IDF in Dubai, December 6, 2011:
Differences in response between exenatide and liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide audits
Ryder, R.E.J., Thong, K.Y., Cull, M.L., Mills, A.P., Walton, C., Winocour, P.H., on behalf of the ABCD nationwide exenatide audit contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
Practical Diabetes International 2010; 27(8): 352-357
Full paper
Practical Diabetes International 2010; 27(8): 352-357
All contributors are listed
K. Y. Thong, B. Jose, N. Sukumar, M. L. Cull, A. P. Mills, T. Sathyapalan, W. Shafiq, A. S. Rigby, C. Walton, R. E. J. Ryder, on behalf of the ABCD nationwide exenatide audit contributors. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
Diabetes, Obesity and Metabolism 2011; 13(8): 703-710
Full paper (ABCD members and audit contributors only):
Diabetes, Obesity and Metabolism 2011; 13(8): 703-710
All contributors are listed
K.Y. Thong, B. Jose, A.D. Blann, M.L. Cull, A.P. Mills, T. Sathyapalan, C. Walton, and R.E.J. Ryder, on behalf of the ABCD nationwide exenatide audit contributors. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
Diabetes Res Clin Pract. 2011; 93(2): e87-e91
Full paper (ABCD members and audit contributors only):
Diabetes Res Clin Pract. 2011; 93(2): e87-e91
All contributors are listed
K.Y. Thong, M.L. Cull, R.E.J. Ryder, C. Walton, on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
Diabetic Medicine 2012; 29(5): 690-692
Full paper (ABCD members and audit contributors only):
Diabetic Medicine 2012; 29(5): 690-6921
All contributors are listed
Bob Ryder and Ken Thong, on behalf of the ABCD nationwide exenatide and nationwide liraglutide audit contributors. Findings from the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
In Hot topics in diabetes, 5th edition, Vora J, ed. Synergy, London, 2012: 49-61
All contributors are listed
Ryder REJ, Thong KY, on behalf of the ABCD nationwide exenatide audit contributors. Incidence of acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
All contributors are listed
KY Thong, REJ Ryder. Was it really pancreatitis from GLP-1 receptor agonist therapy?
Practical Diabetes 2013; 30(8): 310
Full paper
Practical Diabetes 2013; 30(8): 310
All contributors are listed
R. E. J. Ryder, P. Sen Gupta, K. Y. Thong on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis—what happens next? A personal viewpoint
Diabetic Medicine 2013; 30(12): 1510-1511
Full paper (ABCD members and audit contributors only):
Diabetic Medicine 2013; 30(12): 1510-1511
All contributors are listed
KY Thong, P Sen Gupta, ML Cull, KA Adamson, DS Dove, SV Rowles, S Tarpey, C Duncan, J Chalmers, R Harper, P McDonald, U Brennan, C Walton, REJ Ryder on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes
Br J Diabetes Vasc Dis 2014; 14: 52-59
Full paper:
Br J Diabetes Vasc Dis 2014; 14: 52-59
All contributors are listed
K.Y. Thong, B.M. Mcgowan, T. Htay, A. Pernet, C. Kelly, C. Rajeswaran, J. Howell, C. Duncan, B. Inkster, L. Buchanan, S. Kassim, R. Nayer, N.D. Barwell, C. Walton, R.E.J Ryder, ABCD Nationwide Liraglutide Audit contributors. Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit.
Abstract Br J Diabetes 2015; 15(4): 169-172
Full Paper Br J Diabetes 2015; 15(4): 169-17
All contributors are listed
Thomas SJ Crabtree, Susannah Rowles, Stephanie Tarpey, Adele Kennedy, John Chalmers, Rahul Nayar, Amanda Lee, Ken Darzy, Peter Winocour, John Lindsay, Iskandar Idris, Ken Y Thong, Piya Sen Gupta, Amar Puttanna, Pranav Kumar, Robert EJ Ryder, On behalf of ABCD Nationwide Audit Contributors. Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit.
Abstract Br J Diabetes 2019; 19: 118-123
Full Paper Br J Diabetes 2019; 19: 118-123
All contributors are listed
DUK satellite symposium, Glasgow, March 10, 2009
ABCD Spring meeting, Bristol, May 8, 2009
DUK satellite symposium, Liverpool, March 2, 2010 (Response at 6 months)
DUK annual professional conference, Liverpool, March 3, 2010 (Response with time)
ABCD Spring meeting, Newcastle, May 7, 2010 (With insulin)
EASD Stockholm, September 22, 2010
DUK annual professional conference, London, April 1, 2011
ADA Scientific Update Satellite Meeting, San Diego, June 26 2011
ADS/ADEA Annual Scientific Meeting, Perth, August 31, 2011
EASD Scientific Update Satellite Meeting, Lisbon, September 14 2011
IDF Scientific Update Satellite Meeting, Dubai, December 6 2011
IDF Main Meeting, Dubai, December 6 2011
EASD Vienna 2009: R.E.J. Ryder, C. Walton, P.H. Winocour, ABCD nationwide exenatide audit contributors. Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetologia 2009, Vol.52 Supplement1: A741
IDF Montreal 2009: R.E.J. Ryder, C. Walton, P.H. Winocour, ABCD nationwide exenatide audit contributors. Factors accounting for variability in weight and HbA1c response to exenatide in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Abstract Book, 20th World Diabetes Congress, IDF, Montreal, Canada, 18-22 October 2009, pp.582
EASD Stockholm 2010a: K.Y. Thong, R.E.J. Ryder, B. Jose, S. Thozhukat, W. Shafiq, A. Rigby, C. Walton, ABCD nationwide exenatide audit contributors. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit . Diabetologia 2010, Vol.53 Supplement1: S38
EASD Stockholm 2010b: B. Jose, R.E.J. Ryder, K.Y. Thong, S. Thozhukat, W. Shafiq, ABCD nationwide exenatide audit contributors. Safety and efficacy of using exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetologia 2010, Vol.53 Supplement1: S343
ABCD Autumn Meeting, London, 2010a: K.Y. Thong, B. Jose, N. Sukumar, M.L. Cull, A.P. Mills, T. Sathyapalan, W. Shafiq, A. Rigby, C. Walton, R.E.J. Ryder, on behalf of the ABCD nationwide exenatide audit contributors. 16.6% (1 in 6) patients who continued insulin at the time of exenatide start came off insulin in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Audit. Poster 5, ABCD Autumn Meeting 2010
ABCD Autumn Meeting, London, 2010b: R.E.J. Ryder, K.Y. Thong, M.L. Cull, A.P. Mills, C. Walton, K.A. Adamson, D.S. Dove, on behalf of the ABCD nationwide exenatide audit contributors. Problems with the NICE guideline for exenatide exposed in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Poster 7, ABCD Autumn Meeting 2010
Australian Diabetes Society 2011: Ken Y Thong and Bob Ryder on behalf of the ABCD nationwide exenatide and liraglutide audits contributors. Response of HbA1c and weight against time in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. 2011 ADS/ADEA Annual Scientific Meeting Programme, Abstract 062
EASD Lisbon 2011a: R.E.J. Ryder, K.Y. Thong, M.L. Cull, A.P. Mills, C. Walton, ABCD nationwide
exenatide and liraglutide audit contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetologia 2011, Vol.54 Supplement1: S326
EASD Lisbon 2011b: C. Walton, R.E.J. Ryder, M.L. Cull, A.P. Mills, K.Y. Thong, ABCD nationwide
exenatide and liraglutide audit contributors. Factors associated with HbA1c and weight changes at 6 months in theAssociation of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetologia 2011, Vol.54 Supplement1: S326
ABCD Autumn Meeting, London, 2011a: CE Walton, REJ Ryder, ML Cull, AP Mills, KY Thong, , on behalf othe ABCD nationwide exenatide and liraglutide audit contributors. Factors associated with HbA1c and weight changes at 6 months in Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit. Poster 4a, ABCD Autumn Meeting 2011
ABCD Autumn Meeting, London, 2011b: REJ Ryder, KY Thong, ML Cull, A P Mills C Walton. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Poster 4b, ABCD Autumn Meeting 2011
IDF Dubai 2011a: R.E.J. Ryder, K.Y. Thong, M.L. Cull, A.P. Mills, C. Walton, ABCD nationwide exenatide and liraglutide audit contributors. Differences in response between exenatide and liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide audits
Abstract Book, 21st World Diabetes Congress, IDF, Dubai, UAE, 4-8 December 2011. (oral presentation)
IDF Dubai 2011b: K. Thong, K. Darzy, M.L. Cull, A.P. Mills, R.E.J. Ryder, ABCD nationwide
exenatide and liraglutide audit contributors. Switching exenatide or gliptins to liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit
Abstract Book, 21st World Diabetes Congress, IDF, Dubai, UAE, 4-8 December 2011. (poster presentation)
IDF Dubai 2011c: K. Thong, R.E.J. Ryder, C. Walton, ABCD nationwide exenatide and liraglutide audit contributors. Factors associated with HbA1c and weight changes in the Association of British Clinical Diabetologists nationwide GLP-1 agonists audits.
Abstract Book, 21st World Diabetes Congress, IDF, Dubai, UAE, 4-8 December 2011. (poster presentation)
IDF Melbourne 2013: K.Y. Thong, P. Sen Gupta, R.E.J. Ryder, ABCD nationwide exenatide and liraglutide audit contributors. The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits. Abstract Book, 22nd World Diabetes Congress, IDF, Melbourne, Australia, 2-6 December 2013. (poster presentation)
ABCD Spring Meeting, Edinburgh, 2014, abstract 1: KY Thong, P Sen Gupta, ML Cull, KA Adamson, DS Dove, SV Rowles, S Tarpey, C Duncan, J Chalmers, R Harper, P McDonald, U Brennan, C Walton, REJ Ryder on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes: the ABCD nationwide audits. Poster 1, ABCD Spring Meeting 2014
The ABCD nationwide exenatide audit is an independent audit supported by an unrestricted grant from Eli Lilly Ltd
